Immunome, Inc. (IMNM)

US — Healthcare Sector
Peers: ANEB  ADAG  ACRV  ANAB  MLYS  MOLN  MNOV  CSBR  CYT  AVTE  RZLT  ANTX  GANX  TFFP  LIFE  INAB  LTRN  IKNA  CELC 

Automate Your Wheel Strategy on IMNM

With Tiblio's Option Bot, you can configure your own wheel strategy including IMNM - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol IMNM
  • Rev/Share 0.1377
  • Book/Share 3.8676
  • PB 2.3425
  • Debt/Equity 0.0155
  • CurrentRatio 10.4923
  • ROIC -0.6994

 

  • MktCap 788331438.0
  • FreeCF/Share -2.035
  • PFCF -4.8782
  • PE -3.5077
  • Debt/Assets 0.0139
  • DivYield 0
  • ROE -0.8573

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 3
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation IMNM Lake Street -- Buy -- $23 April 2, 2025

News

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
IMNM
Published: May 26, 2025 by: Zacks Investment Research
Sentiment: Positive

The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Read More
image for news Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
IMNM
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

Immunome (IMNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Read More
image for news All You Need to Know About Immunome (IMNM) Rating Upgrade to Buy
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
IMNM
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 249.9% upside potential for Immunome (IMNM). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade

About Immunome, Inc. (IMNM)

  • IPO Date 2020-10-02
  • Website https://immunome.com
  • Industry Biotechnology
  • CEO Dr. Clay B. Siegall Ph.D.
  • Employees 131

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.